Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA +
oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for
epidermal growth factor receptor (EGFR)-expressing mCRC.